"From a small team of only eight people, to now evolving into a national-level specialized and sophisticated 'little giant' enterprise, we deeply feel that choosing Beijing E-Town was the most correct decision," said Gai Wei, president and chief technology officer of Willingmed.

Willingmed, established in 2019, is a leading Beijing E-Town innovator that has been dedicated to precision testing of pathogenic microorganisms. The company focuses on applying metagenomic high-throughput sequencing technology (mNGS) to clinical infection diagnosis, effectively addressing issues such as the limited coverage, low detection rates and poor timeliness associated with traditional testing methods.

"When the company was first established, it was just a small team of eight people. We faced many difficulties, due to insufficient personnel, space and funding," Gai said. After understanding this situation, E-Town actively supported the company to coordinate with relevant departments, laying a solid foundation for the company's rapid development ahead.

In just a few years, in the fertile soil of E-Town, Willingmed has developed by leaps and bounds.

It has grown into a nationally recognized, specialized and sophisticated ‘little giant' enterprise with nearly 300 employees. Not only has it established a research center in Beijing E-Town, it has also set up regional testing delivery centers in Beijing, Hangzhou Guangzhou and elsewhere.

Willingmed's service network now covers over 2,000 tertiary hospitals nationwide, providing precise diagnostic services for infectious disease, respiratory medicine, pediatrics, ICUs and other clinical departments.

Gai said that Willingmed will further advance technological innovation and business expansion and improve comprehensive clinical solutions integrating testing equipment, analysis software and testing reagents. Leveraging its resource advantages, it will continue to expand localization access in hospitals, promoting the advancement of personalized medical care in the field of infectious diseases in China and contributing to supporting the country as a global leader in epidemic prevention and control.